$704M BARDA contract Emergent BioSolutions has been awarded a $704 million contract from BARDA. The manufacturer’s announcement came on Tuesday, revealing their 10-year deal to develop and expand the production of the Ebola treatment, Ebanga. This involves scaling up manufacturing, tech transfers, submitting a supplemental BLA to the FDA, and conducting stability studies. Ebanga received FDA approval for treating Ebola in 2020.
The contract news had a significant impact on the company’s stock price ($EBS), which surged over 17% on Tuesday. Kelly Warfield, Emergent’s SVP of science and development, emphasized the importance of preparedness efforts against the unpredictable Ebola virus, which poses a risk to global health.
Ebola virus has the ability to emerge unexpectedly posing a risk to global health. Its elusive nature makes it difficult to predict when and where an outbreak may occur, which underscores the importance of preparedness efforts against this public health threat,” Kelly
Warfield, Emergent’s SVP of science and development said, in a press
release .
Besides this contract, Emergent has secured other significant deals in 2023. In May, they netted a $120 million contract to manufacture the smallpox vaccine ACAM200 for the Strategic National Stockpile. Additionally, at the beginning of the year, Emergent received a $379.6 million contract to supply reactive skin decontamination lotion to the DOD.
$704M BARDA contract
